EMVision Medical Devices Limited (EMVision or the Company), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to provide the following update to the market. The Company advises that it has completed enrolment of its target 30 stroke patients in its pilot clinical study. The patient datasets are now being processed and will undergo clinical review. Top-line results from the study are expected to be released in the 4th quarter of calendar year 2020. The single-site study of participants with diagnosed ischaemic or haemorrhagic stroke is the first clinical study for EMVision's breakthrough imaging technology. The primary endpoint is the collection of a dataset of stroke patients which improves the understanding of stroke on electromagnetic scattering effects in the brain. The Clinical Trial Summary is part of this announcement as Appendix A. These datasets enable EMVision to advance its imaging algorithm development and observe the correlation of EMVision scans with CT and/or MRI scans. Further, clinician and patient feedback on the operation of EMVision's clinical prototype will be reported on. The outputs from this study feeds into the product development, clinical validation and regulatory strategy for EMVision's 1st generation device for commercialisation.